The news. The narrative. The timeline.
Bureau: Tokyo
Brockman's two days finished with a stake roll-call; Zilis took it the next morning, putting the related-party set on the public record before Cerebras prices.
Twenty-four days into the public methodology fight, NICE's final draft says donanemab does not pass cost-effectiveness — and the June 10 meeting is the only document that changes that.
McGill's cytogel hits 13x fracture toughness, 4x adhesion, sub-five-second formation — and outperforms the clinical product in rodent liver hemorrhage.
Penn-led WIHS analysis: monocyte epigenetic age — but not multi-tissue clocks — predicts non-somatic depression in 440 women, sharpening the assay against the somatic-symptom confound.
LHCb-PAPER-2025-041 anchors the four-sigma B0 K* anomaly at 8.4 inverse femtobarns; Run 3 has cleared roughly three times the 2018 set; discovery sits in the 2030s.